Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Gogou, Pinelopi ^a   Pakos, Emilios ^a   Batistatou, Anna ^a,b   Panelos, Ioannis ^a,b   Briasoulis, Evangelos ^a   Stefanou, Dimitrios ^a,b   Apostolikas, Nikoforos ^c   Tsekeris, Periclis ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b St Savvas Cancer Hospital ^*  (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

B catenin; E cadherin; Liposarcomas; Prognosis; Topoisomerase ii alpha

Indexed keywords

BETA CATENIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FORMALDEHYDE; PARAFFIN; UVOMORULIN; CADHERIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMB AMPUTATION; LIMB TUMOR; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RETROPERITONEAL TUMOR; TUMOR CELL; TUMOR LOCALIZATION; TUMOR VOLUME; CANCER STAGING; ENZYME IMMUNOASSAY; LIMB; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BETA CATENIN; CADHERINS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; EXTREMITIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856475684     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-28     Document Type: Article

References (28)

1. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010, 456(2):167-179. 10.1007/s00428-009-0815-x, 19688222.
2. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005, 353(7):701-711. 10.1056/NEJMra041866, 16107623.
3. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006, 48(1):3-12. 10.1111/j.1365-2559.2005.02284.x, 16359532.
4. Reitan JB, Kaalhus O. Radiotherapy of liposarcomas. Br J Radiol 1980, 53(634):969-975. 10.1259/0007-1285-53-634-969, 7426920.
5. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008, 112(7):1585-1591. 10.1002/cncr.23332, 18278813.
6. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002, 62(11):2993-2998.
7. Sato H, Hasegawa T, Abe Y, Sakai H, Hirohashi S. Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation. Hum Pathol 1999, 30(11):1344-1349. 10.1016/S0046-8177(99)90066-7, 10571515.
8. Moon RT. Wnt/beta-catenin pathway. Sci STKE 2005, 2005(271):cm1. 10.1126/stke.2712005cm1, 15713948.
9. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303(5663):1483-1487. 10.1126/science.1094291, 15001769.
10. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 2008, 27(55):6920-6929. 10.1038/onc.2008.343, 2745643, 19029934.
11. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000, 6(12):4789-4796.
12. Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009, 9(5):327-337. 10.1038/nrc2608, 2730144, 19377505.
13. Esteva FJ, Hortobagyi GN. Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 2009, 27(21):3416-3417. 10.1200/JCO.2009.22.6449, 19470912.
14. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009, 9(5):338-350. 10.1038/nrc2607, 2748742, 19377506.
15. Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG. E-cadherin, b-catenin and topoisomerase II expression in rhabdomyosarcomas. J BUON 2009, 14(2):323-324.
16. Yoo J, Park S, Kang CS, Kang SJ, Kim BK. Expression of E-cadherin and p53 proteins in human soft tissue sarcomas. Arch Pathol Lab Med 2002, 126(1):33-38.
17. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB, Nielsen TO. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005, 18(1):68-74. 10.1038/modpathol.3800272, 15375433.
18. Sakamoto A, Oda Y, Adachi T, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med 2002, 126(9):1071-1078.
19. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480. 10.1016/j.cell.2006.10.018, 17081971.
20. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 2001, 32(3):257-263. 10.1053/hupa.2001.22764, 11274633.
21. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009, 54(3):355-364. 10.1111/j.1365-2559.2009.03231.x, 19236512.
22. Hsu PK, Li AF, Wang YC, Hsieh CC, Huang MH, Hsu WH, Hsu HS. Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg 2008, 135(5):1029-1035. 10.1016/j.jtcvs.2007.11.007, 18455580.
23. Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J. Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol 2010, 23(1):113-122. 10.1038/modpathol.2009.141, 19820688.
24. Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG. Expression of E-cadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas. Clin Transl Oncol 2009, 11(8):548-551. 10.1007/s12094-009-0401-3, 19661031.
25. Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK. DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy. Curr Cancer Drug Targets 2010,
26. Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009, 113(3):457-466. 10.1007/s10549-008-9964-x, 18340528.
27. Endo H, Hirokawa M, Ishimaru N, Tanaka Y, Yamashita M, Sakaki M, Hayashi Y, Sano T. Unique cell membrane expression of topoisomerase-II alpha as a useful diagnostic marker of liposarcoma. Pathol Int 2004, 54(3):145-150. 10.1111/j.1440-1827.2003.01600.x, 14989736.
28. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010, 10(2):249-260. 10.1586/era.09.176, 20132000.